Recursion Pharmaceuticals, Inc. $RXRX Stock Position Lessened by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. decreased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 3.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,167,745 shares of the company’s stock after selling 311,539 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Recursion Pharmaceuticals were worth $41,329,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Clear Creek Financial Management LLC grew its stake in shares of Recursion Pharmaceuticals by 9.8% in the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company’s stock worth $113,000 after purchasing an additional 1,907 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after purchasing an additional 2,026 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Recursion Pharmaceuticals by 16.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,439 shares of the company’s stock worth $78,000 after purchasing an additional 2,219 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Recursion Pharmaceuticals by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 30,864 shares of the company’s stock worth $163,000 after purchasing an additional 2,587 shares in the last quarter. Finally, Rafferty Asset Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 0.5% in the first quarter. Rafferty Asset Management LLC now owns 598,420 shares of the company’s stock valued at $3,166,000 after buying an additional 2,948 shares during the period. Institutional investors own 89.06% of the company’s stock.

Insider Transactions at Recursion Pharmaceuticals

In related news, insider Najat Khan sold 36,599 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the sale, the insider directly owned 668,197 shares of the company’s stock, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Trading Up 4.3%

Shares of NASDAQ RXRX opened at $6.30 on Tuesday. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a market cap of $2.74 billion, a price-to-earnings ratio of -3.54 and a beta of 0.91. The company has a quick ratio of 3.58, a current ratio of 3.58 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $5.19 and a 200-day simple moving average of $5.20.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company had revenue of $19.10 million for the quarter, compared to analysts’ expectations of $15.38 million. During the same period in the prior year, the company earned ($0.40) earnings per share. The company’s revenue for the quarter was up 33.3% on a year-over-year basis. Sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price objective for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus target price of $7.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.